Apellis Pharmaceuticals, Inc. (APLS)
19.94
-0.59
(-2.87%)
USD |
NASDAQ |
Jan 16, 16:00
20.05
+0.11
(+0.55%)
After-Hours: 20:00
Apellis Pharmaceuticals SG&A Expense (TTM): 524.64M for Sept. 30, 2025
SG&A Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
SG&A Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (TTM) Benchmarks
| Amicus Therapeutics, Inc. | 353.07M |
| Alnylam Pharmaceuticals, Inc. | 1.181B |
| Ionis Pharmaceuticals, Inc. | 351.68M |
| Fortress Biotech, Inc. | 108.70M |
| Sarepta Therapeutics, Inc. | 527.29M |